Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen

被引：6

作者：

Kusakabe, Atsunori ^{[1
]}

Kurosaki, Masayuki ^{[2
]}

Itakura, Jun ^{[2
]}

Joko, Kouji ^{[3
]}

Akahane, Takehiro ^{[4
]}

Tsuji, Keiji ^{[5
]}

Kobashi, Haruhiko ^{[6
]}

Sohda, Tetsuro ^{[7
]}

Kimura, Hiroyuki ^{[8
]}

Narita, Ryouichi ^{[9
]}

Furuta, Koichirou ^{[10
]}

Izumi, Namiki ^{[2
]}

机构：

[1] Japanese Red Cross Nagoya Daini Hosp, Dept Gastroenterol, Nagoya, Aichi, Japan

[2] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan

[3] Matsuyama Red Cross Hosp, Ctr Liver Biliary Pancreat Dis, Matsuyama, Ehime, Japan

[4] Japanese Red Cross Ishinomaki Hosp, Dept Gastroenterol, Ishinomaki, Miyagi, Japan

[5] Hiroshima Red Cross Hosp & Atom Bomb Survivors Ho, Dept Gastroenterol, Hiroshima, Japan

[6] Japanese Red Cross Okayama Hosp, Dept Hepatol, Okayama, Japan

[7] Japanese Red Cross Fukuoka Hosp, Dept Hepatol, Fukuoka, Fukuoka, Japan

[8] Japanese Red Cross Kyoto Daiichi Hosp, Dept Gastroenterol, Kyoto, Japan

[9] Oita Red Cross Hosp, Dept Gastroenterol, Oita, Japan

[10] Masuda Red Cross Hosp, Dept Gastroenterol, Masuda, Japan

来源：

HEPATOLOGY RESEARCH | 2019年 / 49卷 / 10期

关键词：

chronic hepatitis C; glecaprevir; pibrentasvir; retreatment; HEPATOCELLULAR-CARCINOMA; JAPANESE PATIENTS; ANTIBODY;

D O I：

10.1111/hepr.13387

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim Rescue therapy for patients with genotype 2 (GT2) chronic hepatitis C who failed prior sofosbuvir (SOF) plus ribavirin (RBV) awaits establishment. This study aims to investigate the efficacy and safety of the fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) (GLE/PIB) for patients with GT2 chronic hepatitis C. Methods In this nationwide observational study undertaken by the Japanese Red Cross Liver Study Group, 28 GT2 patients with prior failure of SOF + RBV were retreated with GLE/PIB for 12 weeks. We evaluated the rate of sustained virologic response (SVR) and adverse events. Results After 4 weeks of therapy, serum hepatitis C virus RNA was below the limit of quantification in all patients. The SVR after 4 and 12 weeks of the end of treatment was validated in 100% (28/28) and 100% (28/28), respectively. The adverse events comprised pruritus (eight patients), fatigue (four patients), and appetite loss (four patients), all of which were mild in severity. Conclusions This study establishes the efficacy of GLE/PIB as retreatment in Japanese patients with GT2 chronic hepatitis C not responding to SOF + RBV.

引用

页码：1121 / 1126

页数：6

共 18 条

[1] Real-world efficacy and safety of sofosbuvir plus ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group [J].

Akahane, Takehiro ;

Kurosaki, Masayuki ;

Itakura, Jun ;

Tsuji, Keiji ;

Joko, Kouji ;

Kimura, Hiroyuki ;

Nasu, Akihiro ;

Ogawa, Chikara ;

Kojima, Yuji ;

Hasebe, Chitomi ;

Wada, Shuichi ;

Uchida, Yasushi ;

Sohda, Tetsuro ;

Suzuki, Hideyuki ;

Yoshida, Hideo ;

Kusakabe, Atsunori ;

Tamada, Takashi ;

Kobashi, Haruhiko ;

Mitsuda, Akeri ;

Kondo, Masahiko ;

Shigeno, Masaya ;

Ide, Yasushi ;

Morita, Atsuhiro ;

Kitamura, Tadashi ;

Abe, Takehiko ;

Izumi, Namiki .

HEPATOLOGY RESEARCH, 2019, 49 (03) :264-270

[2] Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan [J].

Akuta, Norio ;

Sezaki, Hitomi ;

Suzuki, Fumitaka ;

Fujiyama, Shunichiro ;

Kawamura, Yusuke ;

Hosaka, Tetsuya ;

Kobayashi, Masahiro ;

Kobayashi, Mariko ;

Saitoh, Satoshi ;

Suzuki, Yoshiyuki ;

Arase, Yasuji ;

Ikeda, Kenji ;

Kumada, Hiromitsu .

JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (02) :284-290

[3] Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis [J].

Asselah, Tarik ;

Kowdley, Kris V. ;

Zadeikis, Neddie ;

Wang, Stanley ;

Hassanein, Tarek ;

Horsmans, Yves ;

Colombo, Massimo ;

Calinas, Filipe ;

Aguilar, Humberto ;

de Ledinghen, Victor ;

Mantry, Parvez S. ;

Hezode, Christophe ;

Marinho, Rui Tato ;

Agarwal, Kosh ;

Nevens, Frederik ;

Elkhashab, Magdy ;

Kort, Jens ;

Liu, Ran ;

Ng, Teresa I. ;

Krishnan, Preethi ;

Lin, Chih-Wei ;

Mensa, Federico J. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (03) :417-426

[4] Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [J].

Chung, Raymond T. ;

Ghany, Marc G. ;

Kim, Arthur Y. ;

Marks, Kristen M. ;

Naggie, Susanna ;

Vargas, Hugo E. ;

Aronsohn, Andrew I. ;

Bhattacharya, Debika ;

Broder, Tina ;

Falade-Nwulia, O. ;

Fontana, Robert J. ;

Gordon, Stuart C. ;

Heller, Theo ;

Holmberg, Scott D. ;

Jhaveri, Ravi ;

Jonas, Maureen M. ;

Kiser, Jennifer J. ;

Linas, Benjamin P. ;

Lo Re, Vincent, III ;

Morgan, Timothy R. ;

Nahass, Ronald G. ;

Peters, Marion G. ;

Reddy, K. Rajender ;

Reynolds, Andrew ;

Scott, John D. ;

Searson, Gloria ;

Swan, Tracy ;

Terrault, Norah A. ;

Trooskin, Stacey B. ;

Wong, John B. ;

Workowski, Kimberly A. .

CLINICAL INFECTIOUS DISEASES, 2018, 67 (10) :1477-1492

[5] Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis [J].

Fujii, Hideki ;

Kimura, Hiroyuki ;

Kurosaki, Masayuki ;

Hasebe, Chitomi ;

Akahane, Takehiro ;

Yagisawa, Hitoshi ;

Kato, Keizo ;

Yoshida, Hideo ;

Itakura, Jun ;

Sakita, Shinya ;

Satou, Takashi ;

Okada, Kazuhiko ;

Kusakabe, Atsunori ;

Kojima, Yuji ;

Kondo, Masahiko ;

Morita, Atsuhiro ;

Nasu, Akihiro ;

Tamada, Takashi ;

Okushin, Hiroaki ;

Kobashi, Haruhiko ;

Tsuji, Keiji ;

Joko, Kouji ;

Ogawa, Chikara ;

Uchida, Yasushi ;

Mitsuda, Akeri ;

Sohda, Tetsuro ;

Ide, Yasushi ;

Izumi, Namiki .

HEPATOLOGY RESEARCH, 2018, 48 (09) :746-756

[6] Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy [J].

Itakura, Jun ;

Kurosaki, Masayuki ;

Takada, Hitomi ;

Nakakuki, Natsuko ;

Matsuda, Syuya ;

Gondou, Kouichi ;

Asano, Yu ;

Hattori, Nobuhiro ;

Itakura, Yoshie ;

Tamaki, Nobuharu ;

Yasui, Yutaka ;

Suzuki, Shoko ;

Hosokawa, Takanori ;

Tsuchiya, Kaoru ;

Nakanishi, Hiroyuki ;

Takahashi, Yuka ;

Maekawa, Syinya ;

Enomoto, Nobuyuki ;

Izumi, Namiki .

HEPATOLOGY RESEARCH, 2015, 45 (10) :E115-E121

[7] Efficacy of daclatasvir in hepatitis C virus [J].

Izumi, Namiki .

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2014, 12 (09) :1025-1031

[8] Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options [J].

Jacobson, Ira M. ;

Gordon, Stuart C. ;

Kowdley, Kris V. ;

Yoshida, Eric M. ;

Rodriguez-Torres, Maribel ;

Sulkowski, Mark S. ;

Shiffman, Mitchell L. ;

Lawitz, Eric ;

Everson, Gregory ;

Bennett, Michael ;

Schiff, Eugene ;

Al-Assi, M. Tarek ;

Subramanian, G. Mani ;

An, Di ;

Lin, Ming ;

McNally, John ;

Brainard, Diana ;

Symonds, William T. ;

McHutchison, John G. ;

Patel, Keyur ;

Feld, Jordan ;

Pianko, Stephen ;

Nelson, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (20) :1867-1877

[9] Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group [J].

Joko, Kouji ;

Goto, Tohru ;

Watanabe, Hiroshi ;

Mitsuda, Akari ;

Uchida, Yasushi ;

Hasebe, Chitomi ;

Tsuruta, Shotaro ;

Kimura, Hiroyuki ;

Koike, Takero ;

Akamatsu, Takuji ;

Mashiba, Toshie ;

Ochi, Hironori ;

Nakamura, Yoshiko ;

Tsuchiya, Kaoru ;

Kurosaki, Masayuki ;

Izumi, Namiki .

HEPATOLOGY RESEARCH, 2016, 46 (04) :251-258

[10] INTERRELATIONSHIP OF BLOOD-TRANSFUSION, NON-A, NON-B HEPATITIS AND HEPATOCELLULAR-CARCINOMA - ANALYSIS BY DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS [J].

KIYOSAWA, K ;

SODEYAMA, T ;

TANAKA, E ;

GIBO, Y ;

YOSHIZAWA, K ;

NAKANO, Y ;

FURUTA, S ;

AKAHANE, Y ;

NISHIOKA, K ;

PURCELL, RH ;

ALTER, HJ .

HEPATOLOGY, 1990, 12 (04) :671-675

← 1 2 →